KENDALL CHILD: Open Payments
NPI 1255300851 · BOZEMAN, MT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$238 in 11 payments from 8 companies in 2025. Trend: 2023 $684 · 2024 $212 · 2025 $238
Food & beverage: $238
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 2 | $47 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $30 |
| ARRAY BIOPHARMA INC | 1 | $26 |
| ABBVIE INC. | 1 | $23 |
| Novocure Inc. | 1 | $22 |
| ADC THERAPEUTICS AMERICA, INC. | 1 | $19 |
| Celgene Corporation | 1 | $14 |
Products named: KEYTRUDA, SYLVANT, IMFINZI, BRAFTOVI, IMBRUVICA, ZYNLONTA, KEYTRUDA QLEX, REBLOZYL.
Industry payments across MT — which companies pay providers there.
